Kristina Maas-Bauer

List of Publications by Year
in descending order

10	166	1478505	1474206
papers	citations	6	9
		h-index	g-index

10	10	10	258
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects. Blood, 2021, 138, 858-870.	1.4	11
2	Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD. Blood Advances, 2021, 5, 2528-2538.	5.2	7
3	Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Clinical Cancer Research, 2021, 27, 6054-6064.	7.0	23
4	Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 614250.	4.8	5
5	Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease. Frontiers in Immunology, 2019, 10, 1624.	4.8	16
6	Distinct Immune Regulatory Potential of Invariant Natural Killer T (iNKT) Cell Subsets: iNKT2 and iNKT17, but Not iNKT1, Protect from Graft-Versus-Host-Disease. Biology of Blood and Marrow Transplantation, 2019, 25, S1-S2.	2.0	1
7	Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2017, 8, 900.	4.8	50
8	DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. Blood, 2016, 128, 2846-2858.	1.4	43
9	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. Blood, 2016, 128, 4561-4561.	1.4	10
10	DR3 Signaling Modulates the Function of Foxp3+ regulatory T Cells and the Severity of Acute Graft and Host Disease. Blood, 2016, 128, 2148-2148.	1.4	0